Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Identifying predictive features of Clostridium difficile infection recurrence before, during, and after primary antibiotic treatment.

Pakpour S, Bhanvadia A, Zhu R, Amarnani A, Gibbons SM, Gurry T, Alm EJ, Martello LA.

Microbiome. 2017 Nov 13;5(1):148. doi: 10.1186/s40168-017-0368-1.

2.

The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection.

Džunková M, D'Auria G, Xu H, Huang J, Duan Y, Moya A, Kelly CP, Chen X.

Front Cell Infect Microbiol. 2016 Oct 4;6:119. eCollection 2016.

3.

Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization.

Zhang L, Dong D, Jiang C, Li Z, Wang X, Peng Y.

Anaerobe. 2015 Aug;34:1-7. doi: 10.1016/j.anaerobe.2015.03.008. Epub 2015 Mar 26.

PMID:
25817005
4.
5.

Clinical, epidemiological and microbiological characteristics of relapse and re-infection in Clostridium difficile infection.

Gómez S, Chaves F, Orellana MA.

Anaerobe. 2017 Dec;48:147-151. doi: 10.1016/j.anaerobe.2017.08.012. Epub 2017 Aug 19.

PMID:
28830842
6.

Differences of the Fecal Microflora With Clostridium difficile Therapies.

Louie TJ, Byrne B, Emery J, Ward L, Krulicki W, Nguyen D, Wu K, Cannon K.

Clin Infect Dis. 2015 May 15;60 Suppl 2:S91-7. doi: 10.1093/cid/civ252.

PMID:
25922407
7.

Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection.

Seekatz AM, Rao K, Santhosh K, Young VB.

Genome Med. 2016 Apr 27;8(1):47. doi: 10.1186/s13073-016-0298-8.

8.

Existing and investigational therapies for the treatment of Clostridium difficile infection: A focus on narrow spectrum, microbiota-sparing agents.

Maxwell-Scott HG, Goldenberg SD.

Med Mal Infect. 2018 Feb;48(1):1-9. doi: 10.1016/j.medmal.2017.10.008. Epub 2017 Nov 21. Review.

PMID:
29169816
9.

Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection.

Khanna S, Montassier E, Schmidt B, Patel R, Knights D, Pardi DS, Kashyap P.

Aliment Pharmacol Ther. 2016 Oct;44(7):715-727. doi: 10.1111/apt.13750. Epub 2016 Aug 2.

10.

Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.

Mintz M, Khair S, Grewal S, LaComb JF, Park J, Channer B, Rajapakse R, Bucobo JC, Buscaglia JM, Monzur F, Chawla A, Yang J, Robertson CE, Frank DN, Li E.

PLoS One. 2018 Jan 31;13(1):e0190997. doi: 10.1371/journal.pone.0190997. eCollection 2018.

11.

Clostridium difficile Alters the Structure and Metabolism of Distinct Cecal Microbiomes during Initial Infection To Promote Sustained Colonization.

Jenior ML, Leslie JL, Young VB, Schloss PD.

mSphere. 2018 Jun 27;3(3). pii: e00261-18. doi: 10.1128/mSphere.00261-18. Print 2018 Jun 27.

12.

Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls.

Schubert AM, Rogers MA, Ring C, Mogle J, Petrosino JP, Young VB, Aronoff DM, Schloss PD.

MBio. 2014 May 6;5(3):e01021-14. doi: 10.1128/mBio.01021-14.

13.

Longitudinal survey of Clostridium difficile presence and gut microbiota composition in a Belgian nursing home.

Rodriguez C, Taminiau B, Korsak N, Avesani V, Van Broeck J, Brach P, Delmée M, Daube G.

BMC Microbiol. 2016 Oct 1;16(1):229.

14.

Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.

Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W.

Clin Infect Dis. 2012 Aug;55 Suppl 2:S132-42. doi: 10.1093/cid/cis338.

15.

Microbiologic factors affecting Clostridium difficile recurrence.

Chilton CH, Pickering DS, Freeman J.

Clin Microbiol Infect. 2018 May;24(5):476-482. doi: 10.1016/j.cmi.2017.11.017. Epub 2017 Dec 5. Review.

16.

Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection.

Zackular JP, Moore JL, Jordan AT, Juttukonda LJ, Noto MJ, Nicholson MR, Crews JD, Semler MW, Zhang Y, Ware LB, Washington MK, Chazin WJ, Caprioli RM, Skaar EP.

Nat Med. 2016 Nov;22(11):1330-1334. doi: 10.1038/nm.4174. Epub 2016 Sep 26. Erratum in: Nat Med. 2016 Dec 6;22(12 ):1502.

17.

Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles.

Allegretti JR, Kearney S, Li N, Bogart E, Bullock K, Gerber GK, Bry L, Clish CB, Alm E, Korzenik JR.

Aliment Pharmacol Ther. 2016 Jun;43(11):1142-53. doi: 10.1111/apt.13616. Epub 2016 Apr 18.

18.

The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection.

Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB.

Gut Microbes. 2011 May-Jun;2(3):145-58. Epub 2011 May 1.

19.

Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.

Webb BJ, Brunner A, Ford CD, Gazdik MA, Petersen FB, Hoda D.

Transpl Infect Dis. 2016 Aug;18(4):628-33. doi: 10.1111/tid.12550. Epub 2016 Jul 5.

PMID:
27214585
20.

Whole-genome sequencing improves discrimination of relapse from reinfection and identifies transmission events among patients with recurrent Clostridium difficile infections.

Mac Aogáin M, Moloney G, Kilkenny S, Kelleher M, Kelleghan M, Boyle B, Rogers TR.

J Hosp Infect. 2015 Jun;90(2):108-16. doi: 10.1016/j.jhin.2015.01.021. Epub 2015 Feb 26.

PMID:
25935700

Supplemental Content

Support Center